Global Targeted DNA/RNA Sequencing Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Workflow;

Pre-Sequencing, Sequencing, and Data Analysis

By Type;

DNA-Based Targeted Sequencing and RNA-Based Targeted Sequencing

By Application;

Human Biomedical Research, Plant & Animal Sciences, Drug Discovery, and Others

By End Use;

Academic Research, Hospitals & Clinics, Pharma & Biotech Entities, and Other

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn325513657 Published Date: May, 2025 Updated Date: June, 2025

Targeted DNA/RNA Sequencing Market Overview

Targeted DNA/RNA Sequencing Market (USD Million)

Targeted DNA/RNA Sequencing Market was valued at USD 13,069.87 million in the year 2024. The size of this market is expected to increase to USD 39,366.87 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 17.1%.


Global Targeted DNA/RNA Sequencing Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 17.1 %


Study Period2025 - 2031
Base Year2024
CAGR (%)17.1 %
Market Size (2024)USD 13,069.87 Million
Market Size (2031)USD 39,366.87 Million
Market ConcentrationLow
Report Pages368
13,069.87
2024
39,366.87
2031

Major Players

  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies
  • PierianDx
  • Genomatix GmbH
  • GATC Biotech Ag
  • Oxford Nanopore Technologies
  • Macrogen, Inc.
  • Thermo Fisher Scientific
  • QIAGEN

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Targeted DNA/RNA Sequencing Market

Fragmented - Highly competitive market without dominant players


The targeted DNA/RNA sequencing market is gaining significant traction as the healthcare industry increasingly prioritizes precision-based treatments. These sequencing technologies enable focused genetic analysis, offering a sharper alternative to broader genome-wide approaches. Currently, over 55% of personalized therapeutic strategies incorporate targeted sequencing to guide clinical outcomes, underscoring its essential role in tailored healthcare.

Expanding Role in Diagnostic Applications
The integration of targeted sequencing into clinical diagnostics is rapidly growing due to its sensitivity in detecting disease-specific genetic markers. This technology now supports about 48% of molecular diagnostic procedures, particularly in identifying rare mutations, gene fusions, and other biomarkers essential for early disease detection and treatment planning.

Robust Growth in Research Initiatives
The market is also benefitting from a surge in biomedical research and biomarker exploration, particularly within the biopharmaceutical and academic sectors. Targeted sequencing is currently employed in around 52% of translational research programs, playing a crucial role in discovering novel disease mechanisms and therapeutic pathways.

Streamlined Workflows Through Automation
Automation and bioinformatics integration have further advanced the reliability and scalability of targeted sequencing. Automated platforms now contribute to over 40% of sequencing workflows, offering faster turnaround times and minimizing human error. These improvements are enhancing usability and accelerating adoption across laboratories and healthcare settings.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Workflow
    2. Market Snapshot, By Type
    3. Market Snapshot, By Application
    4. Market Snapshot, By End Use
    5. Market Snapshot, By Region
  4. Targeted DNA/RNA Sequencing Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Targeted SSI prevention strategies emerging

        2. Tailored care plans improve outcomes

        3. Better microbial profiling with new tech

      2. Restraints
        1. High Initial Investment Costs
        2. Complex Data Analysis and Interpretation
        3. Data Privacy and Security Concerns
        4. Regulatory Challenges and Compliance Requirements
      3. Opportunities
        1. Expansion of Precision Medicine Initiatives
        2. Integration of Genomic Data into Clinical Practice
        3. Development of Companion Diagnostics
        4. Adoption of Liquid Biopsies for Non-invasive Testing
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Targeted DNA/RNA Sequencing Market, By Workflow, 2021 - 2031 (USD Million)
      1. Pre-sequencing
      2. Sequencing
      3. Data Analysis
    2. Targeted DNA/RNA Sequencing Market, By Type, 2021 - 2031 (USD Million)
      1. DNA Based Targeted Sequencing
      2. RNA Based Targeted Sequencing
    3. Targeted DNA/RNA Sequencing Market, By Application, 2021 - 2031 (USD Million)
      1. Human Biomedical Research
      2. Plant & Animal Sciences
      3. Drug Discovery
      4. Others
    4. Targeted DNA/RNA Sequencing Market, By End Use, 2021 - 2031 (USD Million)
      1. Academic Research
      2. Hospitals & Clinics
      3. Pharma & Biotech Entities
      4. Other
    5. Targeted DNA/RNA Sequencing Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Illumina, Inc.
      2. F. Hoffmann-La Roche Ltd
      3. Agilent Technologies
      4. PierianDx
      5. Genomatix GmbH
      6. GATC Biotech Ag
      7. Oxford Nanopore Technologies
      8. Macrogen, Inc.
      9. Thermo Fisher Scientific
      10. QIAGEN
  7. Analyst Views
  8. Future Outlook of the Market